{"nctId":"NCT00327015","briefTitle":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","startDateStruct":{"date":"2006-05"},"conditions":["Diabetes"],"count":1306,"armGroups":[{"label":"Saxagliptin and Metformin (A)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Metformin","Drug: pioglitazone"]},{"label":"Saxagliptin and Metformin (B)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Metformin","Drug: pioglitazone"]},{"label":"Saxagliptin and Placebo (C)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Placebo","Drug: pioglitazone"]},{"label":"Metformin and Placebo (D)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin","Drug: Placebo","Drug: pioglitazone"]}],"interventions":[{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Metformin","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"pioglitazone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Inadequate blood sugar control\n* No current treatment with other medications to lower blood sugar\n\nExclusion Criteria:\n\n* Major heart, liver or kidney problems\n* Pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy","description":"Mean change from baseline in A1C at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.41","spread":"0.072"},{"groupId":"OG001","value":"9.53","spread":"0.069"},{"groupId":"OG002","value":"9.61","spread":"0.075"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","spread":"0.066"},{"groupId":"OG001","value":"7.02","spread":"0.067"},{"groupId":"OG002","value":"7.86","spread":"0.085"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.53","spread":"0.070"},{"groupId":"OG001","value":"-2.49","spread":"0.069"},{"groupId":"OG002","value":"-1.69","spread":"0.069"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy","description":"Mean change from baseline in FPG at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198.9","spread":"3.17"},{"groupId":"OG001","value":"204.3","spread":"3.35"},{"groupId":"OG002","value":"200.9","spread":"3.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.2","spread":"2.39"},{"groupId":"OG001","value":"140.1","spread":"2.34"},{"groupId":"OG002","value":"169.9","spread":"3.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.8","spread":"2.34"},{"groupId":"OG001","value":"-62.2","spread":"2.34"},{"groupId":"OG002","value":"-30.9","spread":"2.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","description":"Mean change from baseline in FPG at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198.9","spread":"3.17"},{"groupId":"OG001","value":"204.3","spread":"3.35"},{"groupId":"OG002","value":"199.1","spread":"3.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.2","spread":"2.39"},{"groupId":"OG001","value":"140.1","spread":"2.34"},{"groupId":"OG002","value":"152.7","spread":"2.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.8","spread":"2.34"},{"groupId":"OG001","value":"-62.2","spread":"2.34"},{"groupId":"OG002","value":"-47.3","spread":"2.33"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy","description":"Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null},{"groupId":"OG001","value":"59.7","spread":null},{"groupId":"OG002","value":"32.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","description":"Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null},{"groupId":"OG001","value":"59.7","spread":null},{"groupId":"OG002","value":"41.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy","description":"Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55531","spread":"1116.5"},{"groupId":"OG001","value":"57219","spread":"1169.6"},{"groupId":"OG002","value":"57584","spread":"1143.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35324","spread":"890.0"},{"groupId":"OG001","value":"35790","spread":"888.9"},{"groupId":"OG002","value":"41229","spread":"1050.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21080","spread":"836.5"},{"groupId":"OG001","value":"-21336","spread":"869.6"},{"groupId":"OG002","value":"-16054","spread":"826.7"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","description":"Mean change from baseline in A1C at Week 24, adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.41","spread":"0.072"},{"groupId":"OG001","value":"9.53","spread":"0.069"},{"groupId":"OG002","value":"9.43","spread":"0.073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","spread":"0.066"},{"groupId":"OG001","value":"7.02","spread":"0.067"},{"groupId":"OG002","value":"7.48","spread":"0.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.53","spread":"0.070"},{"groupId":"OG001","value":"-2.49","spread":"0.069"},{"groupId":"OG002","value":"-1.99","spread":"0.069"}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","description":"Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55531","spread":"1116.5"},{"groupId":"OG001","value":"57219","spread":"1169.6"},{"groupId":"OG002","value":"57937","spread":"1281.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35324","spread":"890.0"},{"groupId":"OG001","value":"35790","spread":"888.9"},{"groupId":"OG002","value":"42428","spread":"1082.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21080","spread":"836.5"},{"groupId":"OG001","value":"-21336","spread":"869.6"},{"groupId":"OG002","value":"-15005","spread":"857.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy","description":"Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"40.6","spread":null},{"groupId":"OG002","value":"20.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","description":"Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"40.6","spread":null},{"groupId":"OG002","value":"29.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy","description":"Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"21.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","description":"Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"10.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":328},"commonTop":["HEADACHE","DIARRHOEA","NASOPHARYNGITIS","HYPERTENSION","URINARY TRACT INFECTION"]}}}